Merck Revenue Soars, Setting High Bar For Future Growth
Business Development A Priority For New Spending
With pharma sales up 13% in Q3, questions mount about investments in its pipeline to diversify beyond Keytruda and keep the momentum going after its top seller faces biosimilars in 2028.
